Dyne Therapeutics Inc’s recently made public that its CEO & President Cox John unloaded Company’s shares for reported $35402.0 on Sep 05 ’25. In the deal valued at $13.41 per share,2,640 shares were sold. As a result of this transaction, Cox John now holds 199,539 shares worth roughly $2.57 million.
Then, Friedl-Naderer Johanna sold 894 shares, generating $11,863 in total proceeds. Upon selling the shares at $13.27, the Chief Commercial Officer now owns 95,017 shares.
Before that, Friedl-Naderer Johanna sold 144 shares. Dyne Therapeutics Inc shares valued at $1,931 were divested by the Chief Commercial Officer at a price of $13.41 per share. As a result of the transaction, Friedl-Naderer Johanna now holds 94,873 shares, worth roughly $1.22 million.
Raymond James upgraded its Dyne Therapeutics Inc [DYN] rating to a Strong buy from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Bernstein’s analysts, who began to cover the stock in late June with a ‘”a Mkt perform”‘ rating.
Price Performance Review of DYN
On Monday, Dyne Therapeutics Inc [NASDAQ:DYN] saw its stock fall -2.21% to $12.86. Over the last five days, the stock has lost -3.31%. Dyne Therapeutics Inc shares have fallen nearly -60.55% since the year began. Nevertheless, the stocks have fallen -45.42% over the past one year.
How much short interest is there in Dyne Therapeutics Inc?
A steep rise in short interest was recorded in Dyne Therapeutics Inc stocks on 2025-08-29, dropping by -0.26 million shares to a total of 16.04 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 16.31 million shares. There was a decline of -1.63%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 29, 2025 when Evercore ISI began covering the stock and recommended ‘”an Outperform”‘ rating along with a $46 price target.
